Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Johnson & Johnson Lifts Sales Guidance After Q2 Earnings Beat

Published 07/16/2019, 06:43 AM
Updated 07/16/2019, 07:06 AM
© Reuters.

© Reuters.

Investing.com - Johnson & Johnson (NYSE:JNJ) lifted its annual sales outlook for the year after reporting second-quarter earnings that beat consensus on the top and bottom line.

The company reported earnings per share of $2.58 on revenue of $20.56 billion. That represented a 1.6% increase in sales in constant currencies. Earrnings were supported by a $2 billion pretax gain on the sale of part of the company's medical devices business. Analysts polled by Investing.com forecast EPS of $2.44 on revenue of $20.29 billion.

J&J shares trimmed earlier gains after the release and by 7:21 AM ET (11:21 GMT), they were up 0.4% at $135.20 in premarket trade, having stood at $135.84 before the news.

The company raised its guidance for full-year sales to between 3.2% and 3.7% in constant currencies, up from a previous range around 3%. It left its earnings guidance unchanged.

The shares remain under a cloud of lingering uncertainty while J&J seeks to settle thousands of lawsuits - 14,000 according to media estimates - that claim its talcum powder caused ovarian cancer.

The company itself admitted in Tuesday’s release that it was “unable to predict with reasonable certainty the ultimate outcome of legal proceedings.”

Last Friday, the shares fell more than 4% after Bloomberg reported that the U.S. Justice Department is investigating whether the company had hidden knowledge of the product's possible risks from the public.

A grand jury in Washington is examining documents that could help shed light onto what the company may have known about any carcinogens in its products, the report said, citing unnamed sources.

Investing.com analyst Haris Anwar warned ahead of the release that the litigation could continue to pressure the stock for some time, although he was confident that the company has the “company has the resources to fight these claims, thanks to its wide moat and massive cash-generation capabilities."

J&J follows other major healthcare sector earnings this month


On June 18, Bayer AG PK reported second quarter EPS of $0.71 on revenue of $14.5B, compared to forecasts of EPS of $0.69 on revenue of $14.17B.

Helen of Troy Ltd earnings beat analysts' expectations on July 9, with first quarter EPS of $2.06 on revenue of $376.34M. Investing.com analysts expected EPS of $1.69 on revenue of $351.54M

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.